Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri

被引:12
作者
Ellingson, Benjamin M. [2 ,3 ,4 ]
Rand, Scott D. [2 ,3 ]
Malkin, Mark G. [2 ,4 ,5 ]
Schmainda, Kathleen M. [1 ,2 ,3 ]
机构
[1] Med Coll Wisconsin, Dept Biophys, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Translat Brain Tumor Program, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Dept Radiol, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA
[5] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA
基金
美国国家卫生研究院;
关键词
Gliomatosis cerebri; Functional diffusion maps; Diffusion MRI; Non-enhancing glioma; Cancer biomarkers; HIGH-GRADE GLIOMA; CONTRAST ENHANCEMENT; IMAGING BIOMARKER; BRAIN-TUMORS; SURVIVAL; MRI;
D O I
10.1007/s11060-009-0018-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Diffusion-weighted magnetic resonance imaging (DWI) is a sensitive imaging biomarker for tumor cellularity. Functional diffusion maps (fDMs), which examine voxel-by-voxel changes in the apparent diffusion coefficient (ADC) calculated from serial DWIs, have previously been applied to regions of contrast-enhancement; however, application of fDMs to non-enhancing brain tumors has not been pursued. In this case study we demonstrate the utility of applying fDMs to regions of abnormal FLAIR signal intensity in a patient diagnosed with gliomatosis cerebri: a relatively rare, infiltrative, non-enhancing brain tumor. The absolute volume of hypercellularity extracted from fDMs was useful in tracking tumor growth, which correlated in time with a progressive decline in neurological status despite no change in traditional magnetic resonance images. Results of this study demonstrate the value of fDMs, applied to regions of FLAIR abnormal signal intensity, for localizing regions of hypercellularity and for monitoring overall tumor status.
引用
收藏
页码:419 / 423
页数:5
相关论文
共 22 条
[1]  
Barker FG, 1997, CANCER-AM CANCER SOC, V80, P936
[2]   ABSENCE OF CONTRAST ENHANCEMENT ON CT BRAIN-SCANS OF PATIENTS WITH SUPRATENTORIAL MALIGNANT GLIOMAS [J].
CHAMBERLAIN, MC ;
MUROVIC, JA ;
LEVIN, VA .
NEUROLOGY, 1988, 38 (09) :1371-1374
[3]   Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].
Chenevert, TL ;
Stegman, LD ;
Taylor, JMG ;
Robertson, PL ;
Greenberg, HS ;
Rehemtulla, A ;
Ross, BD .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036
[4]  
Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO
[5]  
2-F
[6]  
Ellingson BM, 2009, P INT SOC MAG RESON, V7, P1010
[7]  
Ellingson BM, 2009, P INT SOC MAG RESON, V17, P285
[8]   Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma [J].
Galanaud, D ;
Chinot, O ;
Nicoli, F ;
Confort-Gouny, S ;
Le Fur, Y ;
Barrié-Attarian, M ;
Ranjeva, JP ;
Fuentés, S ;
Viout, P ;
Figarella-Branger, D ;
Cozzone, PJ .
JOURNAL OF NEUROSURGERY, 2003, 98 (02) :269-276
[9]   The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: Histopathological evaluation of a series [J].
Ginsberg, LE ;
Fuller, GN ;
Hashmi, M ;
Leeds, NE ;
Schomer, DF .
SURGICAL NEUROLOGY, 1998, 49 (04) :436-440
[10]   Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma [J].
Hamstra, DA ;
Chenevert, TL ;
Moffat, BA ;
Johnson, TD ;
Meyer, CR ;
Mukherji, SK ;
Quint, DJ ;
Gebarski, SS ;
Fan, XY ;
Tsien, CI ;
Lawrence, TS ;
Junck, L ;
Rehemtulla, A ;
Ross, BD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (46) :16759-16764